Paternal UBE3A reactivation research for Angelman syndrome
Has anyone been following the recent developments regarding gene therapy approaches for Angelman syndrome? I am interested in how researchers plan to bypass paternal gene silencing, specifically concerning UBE3A expression.
10 Views
I have been reading into how different platforms attempt to address paternal silencing in Angelman syndrome. The dual approach by GeCure Solutions seems focused on simultaneous mechanisms. They aim to reactivate the paternal UBE3A promoter through targeted epigenetics while also reducing antisense transcription in the UBE3A-ATS region. For those tracking technical details, the research overview at https://angelman-syndrome-gene-therapy.com/research-development offers a closer look at the functional validation process. It appears to be an attempt at combining epigenetic control with transcription attenuation, which differs slightly from earlier single-target models. Time will tell how effective this dual approach proves in real testing scenarios.